GLP-1 and Incretin Research Protocols

GLP-1 is an incretin hormone released from intestinal L cells after a meal. Its receptor is expressed in pancreatic beta cells, in the gastrointestinal tract, and in hypothalamic nuclei that regulate appetite, which is why agonism at this single receptor produces both glycemic and intake effects.

Dual agonists add GIP receptor activity. GIP is the other major incretin, and the combination has been reported in trial literature to produce larger metabolic effects than GLP-1 agonism alone.

Triple agonists add glucagon receptor activity, which contributes an energy expenditure component through hepatic metabolism rather than acting only on intake and glycemia.

The incretin effect is the observation that glucose taken orally produces a much larger insulin response than the same amount of glucose delivered intravenously. That gap is explained by gut derived hormones, and characterizing it is what opened this entire research class.

Receptor coverage is the axis everything in this category is organized around. Single agonists engage GLP-1 alone. Dual agonists add GIP, a second incretin receptor with its own effects on adipose tissue handling. Triple agonists add glucagon receptor activity, which contributes energy expenditure signaling rather than intake suppression.

Each additional receptor adds effect but also adds interpretive complexity, because outcomes can no longer be attributed to a single pathway. This is the central tradeoff discussed in the comparative literature, and it is why head to head trial data matters more here than in most categories.

Insulin release through these receptors is glucose dependent, meaning the signal scales with circulating glucose rather than firing at a fixed rate. That property is a large part of why the class became a research focus in metabolic study.